Literature DB >> 14740878

Adverse reactions to ivermectin treatment in Simulium neavei-transmitted onchocerciasis.

Walter Kipp1, Jotham Bamhuhiiga, Tom Rubaale, Dietrich W Büttner.   

Abstract

To assess adverse effects of ivermectin treatment in a Simulium neavei-transmitted focus of onchocerciasis, a study was conducted with 1,246 patients infected with Onchocerca volvulus in eight villages in western Uganda. Study participants were treated the first time with a single dose of 150 microg/kg of ivermectin. Adverse reactions to ivermectin were determined through questioning and clinical examination during house-to-house visits to the participants within 48 hours after ivermectin treatment. Overall adverse reactions were observed in 737 (59.1%) patients. Severe reactions were rare (10 patients, 1.4%). Our data show that adverse reactions to ivermectin in an S. neavei-transmitted onchocerciasis focus in western Uganda occur frequently. In spite of the fact that many patients showed adverse reactions to ivermectin, the drug was well accepted and appreciated by the population.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14740878

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  3 in total

1.  Assessment of loiasis and outcomes of ivermectin masstreatment in Ijebu-North, Nigeria.

Authors:  A A Hassan; B Akinsanya; N Iyase; F O Owagboriaye
Journal:  Korean J Parasitol       Date:  2011-06-14       Impact factor: 1.341

2.  Wolbachia endobacteria depletion by doxycycline as antifilarial therapy has macrofilaricidal activity in onchocerciasis: a randomized placebo-controlled study.

Authors:  Achim Hoerauf; Sabine Specht; Marcelle Büttner; Kenneth Pfarr; Sabine Mand; Rolf Fimmers; Yeboah Marfo-Debrekyei; Peter Konadu; Alexander Yaw Debrah; Claudio Bandi; Norbert Brattig; Anna Albers; John Larbi; Linda Batsa; Mark J Taylor; Ohene Adjei; Dietrich W Büttner
Journal:  Med Microbiol Immunol       Date:  2007-11-13       Impact factor: 3.402

3.  A randomized, single-ascending-dose, ivermectin-controlled, double-blind study of moxidectin in Onchocerca volvulus infection.

Authors:  Kwablah Awadzi; Nicholas O Opoku; Simon K Attah; Janis Lazdins-Helds; Annette C Kuesel
Journal:  PLoS Negl Trop Dis       Date:  2014-06-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.